Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillance-Reference-Cited by-同舟云学术

Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillance

Published:2024-08 Issue: Volume: Page:1-6
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Zahedi Fatemeh¹,Jafari Anya²,Nasiri Motlagh Behnam³,Hamedi Seyed Hassan⁴,Salek Roham⁵,Khandoozi Seyedreza⁶,Farshchian Negin⁷,Shahidsales Soodabeh⁵,Mafi Ahmad R²,Hosseini Sare⁵,Amouheidari Alireza⁸,Varshoee Tabrizi Fatemeh⁹,Khanjani Nezhat¹⁰,Ahmadloo Niloofar¹⁰,Dayyani Mahdieh⁹,Khodabakhshi Reza¹¹,Mojahed Mohammad Mahdi¹²,Keshvari Masoumeh²,Fazl Ersi Mitra⁹,Mirsadraee Marjaneh⁹,Izadpanahi Payam⁹,Saadipoor Afshin¹³,Nasrollahi Hamid¹⁰,Anbiaee Robab²,Emadi Torghabeh Ali⁵,Keramati Alireza¹⁴,Amiran Seyed Ahmadreza¹⁵,Bayat Mokhtari Narges⁹,Taghizadeh Kermani Ali⁵,Anvari Kazem⁵,Sadeghi Ivari Mahboobeh⁹,Dayani Malihe¹⁶,Amirabadi Amir¹⁷,Saeidi Saedi Hamid¹⁸,Sabzvari Araz¹⁹,Kafi Hamidreza²⁰,Homaei Shandiz Fatemeh¹⁰

Affiliation:

1. Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran

2. Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3. Department of Radio-Oncology, Shahid Madani Hospital, Tabriz, Iran

4. Radiation Oncology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

5. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

6. Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran

7. Imam Reza Hospital, Kermanshah University of Medicine Sciences, Kermanshah, Iran

8. Department of Radiation Oncology, Isfahan Milad Hospital, Isfahan, Iran

9. Radiotherapy and Oncology Department, Reza Radiotherapy and Oncology Center, Mashhad, Iran

10. Department of Radiation Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

11. Radiation Oncology Department, Fayazbakhsh Hospital, Tehran, Iran

12. Valiasr Oncology Department, Qom University of Medical Sciences, Qom, Iran

13. Department of Radiation Oncology, Erfanniyayesh Hospital, Tehran, Iran

14. Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

15. Department of Internal Medicine, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran

16. Department of Radiation Oncology, Imam Reza Hospital of Kermanshah, Kermanshah, Iran

17. Innovative Medical Research Center, Faculty of Medicine, Islamic Azad University Mashhad Branch, Mashhad, Iran

18. Associated Professor of Radiation Oncology, Guilan University of Medical Sciences, Guilan, Iran

19. CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran

20. Medical Department, Orchid Pharmed Company, Tehran, Iran

Funder

not funded

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2024.2385483

Reference17 articles.

1. Global Burden of Disease Collaborative Network. Global burden of disease study 2019 (GBD 2019) results 2020. Seattle (USA): Institute for Health Metrics and Evaluation (IHME)]. [cited 2023 Aug 21]. Available from: https://vizhub.healthdata.org/gbd-results/

2. The basic biology of HER2

3. Tissue structure, nuclear organization, and gene expression in normal and malignant breast;Bissell MJ;Cancer Res,1999

4. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

5. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic